Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression - PubMed
doi: 10.1111/j.1442-2050.2004.00393.x.
M Miyamoto, T Shichinohe, Y Kawarada, Y Cho, A Fukunaga, S Murakami, H Uehara, H Kaneko, H Hashimoto, Y Murakami, T Itoh, S Okushiba, S Kondo, H Katoh
Affiliations
- PMID: 15230729
- DOI: 10.1111/j.1442-2050.2004.00393.x
Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression
Y Ebihara et al. Dis Esophagus. 2004.
Abstract
The transcription factor E2F-1, a downstream regulator of the p16-cyclinD-Rb pathway, is required for cell cycle progression. Evidence shows that overexpression of E2F-1 can either promote or inhibit the development of tumors, depending on tissue or experimental conditions. However, the clinical impact of E2F-1 expression on esophageal squamous cell carcinoma (ESCC) remains unknown. To analyze E2F-1 expression in ESCC, we investigated the immunoreactivity of E2F-1 and its correlation with clinicopathological features in 122 patients who underwent surgical resection for ESCC. Positive E2F-1 immunostaining was detected in 73 patients (59.8%). Positive E2F-1 immunostaining correlated positively with pathologic stage (P = 0.0103), p-Grade (P = 0.0014) and pT (P = 0.0192). The overall survival rate was worse in patients with E2F-1-positive tumors than in patients with E2F-1-negative tumors (P = 0.0290). Over-expression of E2F-1 is associated with tumor progression and a worse prognosis after surgery in ESCC.
Similar articles
-
Mega S, Miyamoto M, Ebihara Y, Takahashi R, Hase R, Li L, Shichinohe T, Kawarada Y, Uehara H, Kaneko H, Hashimoto H, Murakami Y, Itoh T, Morikawa T, Kondo S. Mega S, et al. Dis Esophagus. 2005;18(2):109-13. doi: 10.1111/j.1442-2050.2005.00463.x. Dis Esophagus. 2005. PMID: 16053486
-
Kwong RA, Nguyen TV, Bova RJ, Kench JG, Cole IE, Musgrove EA, Henshall SM, Sutherland RL. Kwong RA, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3705-11. Clin Cancer Res. 2003. PMID: 14506162
-
Yamazaki K, Hasegawa M, Ohoka I, Hanami K, Asoh A, Nagao T, Sugano I, Ishida Y. Yamazaki K, et al. J Clin Pathol. 2005 Sep;58(9):904-10. doi: 10.1136/jcp.2004.023127. J Clin Pathol. 2005. PMID: 16126868 Free PMC article.
-
Protein alterations in ESCC and clinical implications: a review.
Lin DC, Du XL, Wang MR. Lin DC, et al. Dis Esophagus. 2009;22(1):9-20. doi: 10.1111/j.1442-2050.2008.00845.x. Epub 2008 Jun 17. Dis Esophagus. 2009. PMID: 18564170 Review.
-
E2F transcription factors and digestive system malignancies: how much do we know?
Xanthoulis A, Tiniakos DG. Xanthoulis A, et al. World J Gastroenterol. 2013 Jun 7;19(21):3189-98. doi: 10.3748/wjg.v19.i21.3189. World J Gastroenterol. 2013. PMID: 23745020 Free PMC article. Review.
Cited by
-
Wang SN, Wang LT, Sun DP, Chai CY, Hsi E, Kuo HT, Yokoyama KK, Hsu SH. Wang SN, et al. Oncotarget. 2016 Jun 14;7(24):36924-36939. doi: 10.18632/oncotarget.9228. Oncotarget. 2016. PMID: 27175585 Free PMC article.
-
Liu CY, Huang CS, Huang CC, Ku WC, Shih HY, Huang CJ. Liu CY, et al. Cancers (Basel). 2021 Oct 31;13(21):5486. doi: 10.3390/cancers13215486. Cancers (Basel). 2021. PMID: 34771648 Free PMC article.
-
Role of E2F-1 and its involving pathway in esophageal squamous cell carcinoma.
Wang W, Shen L, Sun Y, Dong B, Chen K. Wang W, et al. Thorac Cancer. 2014 Mar;5(2):139-48. doi: 10.1111/1759-7714.12061. Epub 2014 Mar 3. Thorac Cancer. 2014. PMID: 26766991 Free PMC article.
-
Truscott M, Harada R, Vadnais C, Robert F, Nepveu A. Truscott M, et al. Mol Cell Biol. 2008 May;28(10):3127-38. doi: 10.1128/MCB.02089-07. Epub 2008 Mar 17. Mol Cell Biol. 2008. PMID: 18347061 Free PMC article.
-
Samaka RM, Aiad HA, Kandil MA, Asaad NY, Holah NS. Samaka RM, et al. Anal Cell Pathol (Amst). 2015;2015:919834. doi: 10.1155/2015/919834. Epub 2015 Oct 27. Anal Cell Pathol (Amst). 2015. PMID: 26601052 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical